Lost in translation by Petsko, Gregory A
Francis Collins, the current director of the NIH (who, I 
might add, has got oﬀ    to an excellent start), made a 
somewhat provocative remark after assuming his new 
position last year. Interviewed for Th  e  New York Times 
last October (5 October 2009; http://www.nytimes.
com/2009/10/06/health/06nih.html?pagewanted=all), 
Collins is quoted as saying, “We’re not the National 
Institutes of Basic Sciences, we’re the National Institutes 
of Health.” Th  is remark came in the context of Collins’ 
declared wish to encourage academic researchers to 
consider commercializing their ideas or pursuing drug 
development in universities, given the increasingly 
barren state of pharmaceutical company labs.
Th   is reminded me of an article I read some time ago, 
which I largely agreed with but which made me hopping 
mad at the same time. It was ‘Big biology is here to stay’ 
by Steven Wiley, a Paciﬁ  c Northwest National Laboratory 
Fellow and director of PNNL’s Biomolecular Systems 
Initiative, which appeared in the Th  e Scientist (http://
www.the-scientist.com/article/display/54854). Subtitled 
‘Why R01-funded biologists should throw their support 
behind large-scale science projects’, the thesis of the 
article was that, “Th   e business of the National Institutes 
of Health (NIH) is to fund research that improves 
people’s health, not fund our personal research projects.” 
In the article Wiley confesses that he originally thought 
the Human Genome Project would be a waste of money, 
but now thinks “we were all wrong”. He goes on to say 
that, “Starting new, large-scale research projects was a 
clear demonstration that NIH was willing to try new 
approaches to accelerate biomedical research… trying to 
shift funds away from these large projects will ensure that 
they do fail, and will be self-defeating in the long run. 
We’d better hope these projects are successful, and we 
should do all we can to help them.”
Now, given my well known views on the ascendancy of 
big science over little science, and the increasing ten-
dency to direct research from the top down by bureau-
cratically initiated programs, you may be wondering why 
I say that I largely agree with Wiley’s sentiments. Th  e 
reason is that neither Wiley’s column nor Collins’ remark 
was really about big science in the sense that I mean it. I 
dislike large-scale, top-down programs; they are referring 
to projects aimed at translating the ﬁ  ndings of biomedical 
research into therapies for human disease. Many of the 
big science projects that I regard as not worth continuing, 
like the structural genomics initiative, aim to advance 
fundamental knowledge rather than produce direct 
health beneﬁ  ts, and many of the others, like the eﬀ  ort to 
associate common genomic polymorphisms with risk for 
disease, are simply not likely to produce signiﬁ  cant health 
beneﬁ  ts no matter what their intention was.
I have no problem with good science, whether it’s large 
or small, although I do believe we must always have both 
sizes, and that research driven by the curiosity of the 
individual investigator should be the predominant kind 
we support. I agreed with Wiley (and Collins) because 
they were in fact making a case for good science aimed 
directly at ﬁ  nding cures versus science aimed at expand-
ing our basic knowledge of biology - in other words, 
translational research versus basic research. And that is 
also precisely why the Wiley article (and the Collins 
remark) made me angry. It wasn’t what they said. It was 
the way they chose to talk about it.
I hate translational research. Now, before you either 
applaud or burst a blood vessel, you should know 
something else: I also hate basic research. Or, to be precise, 
I hate the terms ‘translational research’ and ‘basic research’.
If there’s a theme, besides the transformative nature of 
the age of genomics, that runs through the columns I’ve 
written for the past 10 years, it’s that the words we use to 
describe something are incredibly important, and often 
get us into all kinds of trouble. We should never have 
used ‘therapeutic cloning’ to describe somatic cell 
nuclear transfer; having the word ‘cloning’ in there 
allowed religious fundamentalists to deﬁ  ne the terms of 
the debate about embryonic stem cells. We should not 
have let the term ‘chemical’ become a pejorative. ‘Global 
warming’ is a poor phrase to rouse people to change their 
way of life - ‘climate crisis’ might have been much better 
(and also would have had the virtue of being alliterative). 
But of all the poorly chosen words in recent scientiﬁ  c 
history, few are as bad as ‘translational research’ and 
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dominate our discussion of funding priorities? It’s every-
thing we should avoid. It sets up a dichotomy that is 
bound to confuse the lay public; it divides us into two 
warring camps, competing for attention and resources; 
and it implies, falsely, that there may be a diﬀ  erence in 
value in the kind of work that we do based on its intent.
We should make this our mantra as life scientists: there 
is no such thing as basic research and no such thing as 
translational research. Th  ere is only research, period. If 
we must put an adjective in front of it, then let’s use 
‘biomedical’. But we simply have to stop talking about our 
science as though there were diﬀ  erent versions of it, with 
diﬀ  erent objectives and diﬀ  erent implicit worth.
Do you really think that what is called basic research 
could exist if the public, and its elected oﬃ   cials, did not 
believe they would ultimately derive some beneﬁ  t from 
it? And what would translational research have to trans-
late if no new fundamental discoveries were made? Th  ese 
two feuding city-states need each other, and ought to be 
united in common cause against the invading empire of 
ignorance, superstition, and anti-intellectualism. But 
more than that: they shouldn’t be separate states in the 
ﬁ  rst place.
We simply have to stop talking about research as 
though there were two kinds. Th   ere aren’t. When we start 
to use those divisive terms, we have to check ourselves. 
When a scientiﬁ  c oﬃ   cial like Francis Collins uses them, 
we have to urge him not to. And we have to make peace 
within our own community, with both sides in the 
current dispute recognizing not only that they need each 
other to survive, but that our enterprise is seamless - a 
continuum from the most basic discovery to its most 
practical application. If Barnett Rosenberg hadn’t 
wondered what would happen to Escherichia coli cells 
when they were placed in an electric ﬁ   eld, we would 
never have known that cisplatin, which doesn’t have a 
single atom of carbon in it, was a drug that could block 
cell growth and division. But if a number of other 
scientists hadn’t worked with him to follow the implica-
tions of that observation and test cisplatin on cancer 
models in animals, and then to ﬁ   ght for its eventual 
testing on people, testicular cancer would not be a 
curable disease, and Lance Armstrong would probably be 
dead. Th  ere is no basic research and no translational 
research; there is only research, in all its frustrating, 
expensive, confusing magniﬁ  cence. Why should we take 
one of the greatest monuments to the human spirit and 
turn it into the Balkans?
But if you agree with me, and I hope you do, you are 
probably wondering, “Well how, then, can we explain to 
the public that you have to support the Barney 
Rosenbergs of the world doing things just to satisfy their 
own curiosity in order to get the cures you want? At least 
the way Collins and Wiley talk about research, you can 
piggyback support for basic research onto the ﬂ  ood of 
money coming in for translating discoveries into therapies. 
If you can’t talk about the two parts of the enterprise that 
way, how do you get support for it at all?”
Th   e answer, I think, is that we haven’t been making the 
argument for the support of biomedical research as well 
as we could. Wiley is wrong when he says, “Th  e  business 
of the NIH is to fund research that improves people’s 
health, not fund our personal research projects.” Th  e 
business of the NIH is to fund both, because they are the 
same thing. But how do we get that point across? Next 
month, I’ll tell you.
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